An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer in clinical practice. Data will be collected for each patient for 18 months from initiation of Avastin therapy.
Non-Squamous Non-Small Cell Lung Cancer
Progression-free survival, 18 months
Clinical (diagnosis, therapies, comorbidity) and demographic characteristics of patients initiated on Avastin treatment, 18 months|Modality of treatment with Avastin (dose, duration, associated chemotherapy), 18 months|Overall survival, 18 months|Safety: Incidence of adverse events, 18 months|Quality of Life: Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire, 18 months|Treatment of non-squamous NSCLC in clinical practice, 18 months
This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer in clinical practice. Data will be collected for each patient for 18 months from initiation of Avastin therapy.